ProPhase Labs announces BE-Smart's validation for esophageal disease diagnostics, achieving over 95% success in detecting critical biomarkers. ProPhase Labs Inc. announced the successful validation of ...
Cornell scientists have taken a major step toward developing a safe, reversible, long-acting and 100% effective nonhormonal male contraceptive ...
Projections for Pharmaloz Manufacturing: Approximately $16-17 Million in Revenue, $6-7 Million in Pre-Tax Earnings for 2025 Strategic Partnership Discussions Begin for BE-Smart Esophageal Cancer Test ...
Company Actively Pursuing Strategic Alternatives Including the Potential Sale of Nebula Genomics and DNA Complete to Unlock Immediate Cash GARDEN CITY, NY, Feb. 20, 2025 (GLOBE NEWSWIRE) -- ProPhase ...
ProPhase Labs, Inc., a company specializing in pharmaceutical preparations with a current market capitalization of $8.16 million, has announced an executive shift with the departure of its current ...
ProPhase Labs Inc. (Nasdaq: PRPH) (“ProPhase”) is a next-generation biotech, genomics and diagnostics company. Our goal is to create a healthier world with bold action and the power of insight. We’re ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results